Brendan M. Everett MD, MPH
Director, General Cardiology Inpatient Service, Cardiovascular Division, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School; Investigator, Center for Cardiovascular Disease Prevention, Boston, MassachusettsDr. Brendan M. Everett is general and preventive cardiologist at Brigham and Women’s Hospital (BWH) and an Associate Professor of Medicine at Harvard Medical School (HMS). Dr. Everett has a long-standing interest in preventing heart attack, hear failure, stroke, amputation, and death in patients with type 2 diabetes. Together with Dr. Deborah Wexler and Dr. Robert J. Glynn, he is running a large, comparative effectiveness trial in patients with type 2 diabetes and cardiovascular disease or at high risk. This trial, called the PRECIDENTD study, represents the next step to figure out how best to help patients with diabetes live free of heart and vascular disease.
Disclosures
Dr Everett reports research support from Novo Nordisk and PCORI; consulting fees from the American Heart Association, Eli Lilly and Company, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, and Novo Nordisk; and royalties from UpToDate.
Recent Contributions to PracticeUpdate:
- Prediction of New-Onset Heart Failure in Patients With Type 2 Diabetes Derived From ALTITUDE and CANVAS
- Further LDL Lowering in Patients With Very Low LDL Reduces Vascular Events
- Evolocumab for Cardiovascular Disease
- Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population
- Predictive Validity of the ACC/AHA Pooled Cohort Risk Equations in Predicting All-Cause and Cardiovascular Disease–Specific Mortality